Argenx (argenx) is currently working on a therapy for the treatment of acute myeloid leukemia (AML), and during the holiday season, the company has revealed how it is going.
Namely, preclinical data on CD70/CD27 pathway that further reveals data on the antybody ARGX-110 AML therapy is showing how the antibody acts in combination with azacitidine for patients who were newly diagnosed.
The data was published by prof. Adrian Ochsenbein at Swiss university of Bern, and he said that DC7/CD27 was highly expressed on AML leukemic stem cells and blasts in newly diagnosed patients, regardless of patients’ risk class.
Chief Medical Officer of argenx, Nicolas Leupin, is very satisfied with the published data which were announced from Prof Ochsenbein’s lab, as it continues to support further testing ARGX-110
Leupin said: “We are very committed to our recently initiated Phase I/II study of ARGX-110 in combination with standard of care azacitidine as we believe this target represents an innovative and differentiated approach to the disease, further proven by this seminal data underscoring the role of CD70 in acute myeloid leukaemia (AML).”
argenx’s stocks on December 29, 2016, at 08:59 – were € 14.71.